Myasthenia gravis during pregnancy

Simone Ferrero, Francesca Esposito, Mariangela Biamonti, Giorgio Bentivoglio, Nicola Ragni

Research output: Contribution to journalArticle

Abstract

Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.

Original languageEnglish
Pages (from-to)979-988
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Myasthenia Gravis
Pregnancy
Epidural Anesthesia
Cholinesterase Inhibitors
Azathioprine
Psychological Stress
Cesarean Section
Respiratory Insufficiency
Postpartum Period
Cyclosporine
Obstetrics
Adrenal Cortex Hormones
Therapeutics

Keywords

  • Delivery
  • Diagnosis
  • Myasthenia gravis
  • Pregnancy
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Ferrero, S., Esposito, F., Biamonti, M., Bentivoglio, G., & Ragni, N. (2008). Myasthenia gravis during pregnancy. Expert Review of Neurotherapeutics, 8(6), 979-988. https://doi.org/10.1586/14737175.8.6.979

Myasthenia gravis during pregnancy. / Ferrero, Simone; Esposito, Francesca; Biamonti, Mariangela; Bentivoglio, Giorgio; Ragni, Nicola.

In: Expert Review of Neurotherapeutics, Vol. 8, No. 6, 06.2008, p. 979-988.

Research output: Contribution to journalArticle

Ferrero, S, Esposito, F, Biamonti, M, Bentivoglio, G & Ragni, N 2008, 'Myasthenia gravis during pregnancy', Expert Review of Neurotherapeutics, vol. 8, no. 6, pp. 979-988. https://doi.org/10.1586/14737175.8.6.979
Ferrero, Simone ; Esposito, Francesca ; Biamonti, Mariangela ; Bentivoglio, Giorgio ; Ragni, Nicola. / Myasthenia gravis during pregnancy. In: Expert Review of Neurotherapeutics. 2008 ; Vol. 8, No. 6. pp. 979-988.
@article{a002a17e4cab4fc489298886aa4e139c,
title = "Myasthenia gravis during pregnancy",
abstract = "Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.",
keywords = "Delivery, Diagnosis, Myasthenia gravis, Pregnancy, Treatment",
author = "Simone Ferrero and Francesca Esposito and Mariangela Biamonti and Giorgio Bentivoglio and Nicola Ragni",
year = "2008",
month = "6",
doi = "10.1586/14737175.8.6.979",
language = "English",
volume = "8",
pages = "979--988",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Myasthenia gravis during pregnancy

AU - Ferrero, Simone

AU - Esposito, Francesca

AU - Biamonti, Mariangela

AU - Bentivoglio, Giorgio

AU - Ragni, Nicola

PY - 2008/6

Y1 - 2008/6

N2 - Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.

AB - Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.

KW - Delivery

KW - Diagnosis

KW - Myasthenia gravis

KW - Pregnancy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=45749093276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749093276&partnerID=8YFLogxK

U2 - 10.1586/14737175.8.6.979

DO - 10.1586/14737175.8.6.979

M3 - Article

C2 - 18505362

AN - SCOPUS:45749093276

VL - 8

SP - 979

EP - 988

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 6

ER -